ubmslateOT-logo-ubm

OT mobile menu

Search form

Topics:

Leukemia & Lymphoma

LLS Precision Medicine Trial May Change Treatment Paradigm for AML Patients

The Leukemia & Lymphoma Society will head up the Beat AML Master Trial, which will use a precision medicine protocol under the support and guidance from the FDA. Image © Minerva Studio/Shutterstock.com 

Leukemia & Lymphoma

We spoke with Dr. Anas Younes about the molecular characteristics of diffuse large B-cell lymphoma.

The emergence of ibrutinib-resistant chronic lymphocytic leukemia (CLL) can be detected prior to clinical relapse, according to an analysis of patients from four ibrutinib trials.

Despite significant toxicities, idelalisib improved time to progression for patients with treatment-resistant chronic lymphoblastic leukemia.

Combined miniCHOP and treatment with the fully-human anti-CD20 monoclonal antibody ofatumumab is associated with improved overall survival among elderly patients diagnosed with diffuse large B-cell lymphoma.

Stem cells that give rise to acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) express higher levels of the CD99 cell surface protein-sugar molecule than normal stem cells.

One of the confounding issues with treating patients with immunotherapy for hematologic diseases is the risk of relapse that can occur during and after treatment.

We spoke with Dr. Mikkael Sekeres on the difficulty of cancer patients meeting eligibility criteria for clinical trials.

Pages

Subscribe to Leukemia & Lymphoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.